• Explore /
  • Poster
  • / Update results of paclitaxel and cisplatin in combination with anlotinib as first-line regimen for advanced esophageal squamous cell carcinoma (ESCC): A multicenter, single-arm, open-label phase Ⅱ clinical trial.

Update results of paclitaxel and cisplatin in combination with anlotinib as first-line regimen for advanced esophageal squamous cell carcinoma (ESCC): A multicenter, single-arm, open-label phase Ⅱ clinical trial.

Abstract Poster

Authors

null

Junsheng Wang

AnYang Tumor Hospital, Anyang, China

Junsheng Wang , Suxia Luo , Ning Li , Tao Wu , Yonggui Hong , Yanzhen Guo , Yufeng Cheng , Baosheng Li , Bingxu Tan

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session: Esophageal and Gastric Cancer

Track

Esophageal and Gastric Cancer

Sub Track

Patient-Reported Outcomes and Real-World Evidence

Clinical Trial Registration Number

NCT04063683

Citation

J Clin Oncol 39, 2021 (suppl 3; abstr 181)

DOI

10.1200/JCO.2021.39.3_suppl.181

Abstract #

181

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Shui-Ling Jin

First Author: Xiuli Yang

First Author: Junsheng Wang

First Author: Pei Dong